Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spinal surgery bleeding: which dose of TXA works best?

NCT ID NCT07288697

Disease control Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested two doses of the drug tranexamic acid (TXA) in 62 adults undergoing multilevel spinal surgery. The goal was to see which dose better reduces blood loss and the need for blood transfusions. Results could help surgeons choose the safest and most effective dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid (TXA)
What this could lead to
If successful, this could help determine the best dose of tranexamic acid to reduce blood loss and transfusions during spinal surgery.
What could go wrong
This is a small, completed trial with only 62 participants. Results may not apply to all patients or surgeries, and dosing differences may not lead to clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Nov 2023

Finished

Apr 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between 18-65 years * Scheduled for elective ≥3-level spinal stabilization surgery under general anesthesia Exclusion Criteria: * History of thromboembolic events * Myocardial infarction * Stroke * Hepatic or renal failure, * Known allergy to TXA * Bleeding or coagulation disorders, * ASA physical status IV * Trauma or tumor surgery * Refusal to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood loss, surgical are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical Hemorrhage intervertebral disk degenerative disorder spondylosis vertebral column disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood loss, surgical Degenerative spine disease Spinal disorders

Contacts and locations

Locations

  • Kartal Dr. Lütfi Kırdar Şehir Hastanesi

    Istanbul, 34865, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.